BACKGROUND: Alterations in autophagy have been reported in hypertrophic cardiomyopathy (HCM) caused by Danon disease, Vici syndrome, or LEOPARD syndrome, but not in HCM caused by mutations in genes encoding sarcomeric proteins, which account for most of HCM cases. MYBPC3, encoding cMyBP-C (cardiac myosin-binding protein C), is the most frequently mutated HCM gene.
A well-controlled balance between protein synthesis and degradation is crucial for cellular homeostasis. The major pathways for degradation of cellular proteins are the ubiquitinproteasome system and the autophagy-lysosomal pathway. 1 Autophagy is defined by the degradation of cellular material within the lysosome. It is a crucial process, because it removes damaged proteins and organelles, supplies energy, and maintains proper metabolism. Insufficient autophagy may lead to energy deficiency and proteotoxicity, whereas overactive autophagy can cause cell death. The genes and cellular processes that underlie autophagy are conserved from yeast to mammals and can be selective or nonselective. The most prevalent form of autophagy is called macroautophagy (hereafter autophagy), where a double-membrane vesicle, the phagophore, is formed and subsequently matures into an autophagosome, eventually fusing with a lysosome for degradation of its contents. 2 Postmitotic cells such as neurons or cardiomyocytes are particularly dependent on energy and protein quality control. Although altered protein quality control mechanisms have been long correlated to neurological diseases, 3 only a few cardiac diseases are known to be associated with defective autophagy. These include Danon disease, 4 ,5 LEOPARD syndrome, 6 Vici syndrome, 7, 8 desmin-related cardiomyopathy, [9] [10] [11] diabetic cardiomyopathy, 12 dilated cardiomyopathy caused by lamin A/C (LMNA) mutations, 13, 14 and left ventricular noncompaction caused by pleckstrin homology domain-containing family M, member 2 (PLEKHM2) mutations. 15 In most of these cardiomyopathies, there is a defect in a gene encoding a protein, which is involved in the autophagy-lysosomal pathway, either by acting directly on it or by inducing protein accumulation.
To the best of our knowledge, there is no evidence of altered autophagy in sarcomeropathy leading to hypertrophic cardiomyopathy (HCM) or dilated cardiomyopathy. HCM is an autosomal dominant disorder, characterized by left ventricular hypertrophy and diastolic dysfunction and has an estimated prevalence of 1:500 in the general population. 16 The MYBPC3 gene, encoding cMyBP-C (cardiac myosinbinding protein C), is frequently mutated in HCM, representing 40% to 50% of all HCM mutations. 17, 18 cMyBP-C interacts with myosin, titin, and actin and plays an important role in cardiac contraction and relaxation. 17, [19] [20] [21] We previously reported impairment of the ubiquitin-proteasome system and elevated protein levels of autophagic markers such as p62 (sequestosome-1 protein), a marker for ubiquitinated protein aggregates, and microtubule-associated protein 1 light chain 3 (LC3)-II, an indicator of autophagosome number, in 60-week-old Mybpc3-targeted knockin mice that develop left ventricular hypertrophy and cardiac dysfunction. [22] [23] [24] [25] [26] These mice carry at the homozygous state the human c.772G>A MYBPC3 transition that results in a low level of mutant protein. In the present study, we investigated whether autophagy is altered in patients with HCM and knockin mice and whether activation of autophagy could ameliorate cardiomyopathy in knockin mice.
METHODS
Expanded Methods are available in the Data Supplement.
Human Samples
Human samples were obtained from septal myectomies of patients with HCM carrying MYBPC3 mutations, from nonfailing human heart tissue not suitable for transplantation or from donors that did not die from cardiac disease but of another cause (nonfailing). 27 All materials from patients and donors were taken with informed consent of the donors and
WHAT IS NEW?
• This is the first study to link altered autophagy to hypertrophic cardiomyopathy (HCM) in humans and mice with a sarcomeric protein gene mutation.
• Myectomy samples from patients with MYBPC3 mutations had altered expression of both genes and proteins involved in autophagy, suggesting impaired autophagy in HCM.
• In Mybpc3-targeted knockin mice with HCM, autophagy markers accumulated over time and autophagic flux was impaired.
• mTORC1 (mammalian target of rapamycin complex 1), a key negative regulator of autophagy, was activated in the knockin mice. This was associated with increased phosphorylation of the serine threonine kinase Akt.
• Rapamycin and caloric restriction decrease mTORC1 activity. Both treatments led to a reduction in hypertrophy and the restoration of the defective autophagic flux in the knockin mice.
WHAT ARE THE CLINICAL IMPLICATIONS?
• The MYBPC3 gene, encoding cMyBP-C (cardiac myosin-binding protein C), is frequently mutated in HCM, representing 40% to 50% of all HCM mutations.
• Up to now, there are only general treatments like calcium channel blocker and β-blocker, septal myectomy, ethanol ablation, and heart transplantation available for HCM.
• Our data suggest that activation of autophagy may hold promise as a treatment to rescue HCM induced by MYBPC3 mutations.
with approval of the local ethical boards and according to the Declaration of Helsinki.
Animals
The 
Echocardiography
Transthoracic echocardiography was performed using the Vevo 2100 System (VisualSonics, Toronto, Canada) as described previously.
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Autophagic Flux Measurement
To measure the autophagic flux in vivo, mice were injected intraperitoneally with 40 mg/kg leupeptin (Sigma Aldrich, L-8511) or sodium chloride (500 µL) as described previously.
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Experimental Diet
Eleven-week-old knockin and wild-type (WT) mice were kept on caloric restriction (CR), rapamycin, or control diet for 9 weeks. All diets were based on LabDiet 5LG6 (TestDiet) including Eudragit S100 (rapamycin coating material). Mice kept on CR were fed ≈20% less in the first week and then ≈40% less for the following 8 weeks than control mice. It was assumed that a 30 g mouse eats about 5 g per day. Mice were kept under tight observation and were regularly weighed. Mice on rapamycin diet received ≈2.24 mg/kg rapamycin (Rapamycin Holdings) encapsulated in Eudragit S100 daily. Echocardiography was performed at the beginning and at the end of the experiment. The autophagic flux was measured at the end of the experiment.
Electron Microscopy
Mouse hearts were initially fixed by perfusion with 1% paraformaldehyde/2% (vol/vol) glutaraldehyde in cardioplegic solution (50 mmol/L KCl, 5% dextrose in PBS) and next in 1% paraformaldehyde/2% (vol/vol) glutaraldehyde in 0.1 mol/L cacodylate buffer, pH 7.2. The heart was removed and immersed into the latter fixative (ice cold) and then left and right ventricular free walls and septa were isolated. Each region was divided into small fragments and fixed further in the same fixative at 4°C and then post-fixed/stained in 1% OSO 4 (in water) before dehydration in acetone and embedding in epoxy resin. Ultrathin sections were counterstained with uranium and lead salts. Images were acquired on a Hitachi 7600 electron microscope equipped with an Advanced Microscopy Techniques digital camera. 
Statistical Analysis
RESULTS
Autophagy Is Altered in Patients With HCM and Knockin Mice
We evaluated p62, beclin-1, and LC3 protein levels in myectomy samples from patients carrying MYBPC3 mutations ( Table I in the Data Supplement). Whereas p62, beclin-1, and LC3-I levels did not differ between HCM and nonfailing samples ( Figure 1A through 1D), LC3-II protein levels were 2.6-fold higher in HCM (Figure 1A and 1E). We next quantified the expression of a customized panel of human genes regulated in heart failure, arrhythmias, and autophagy in cardiac RNA pools of HCM and nonfailing individuals. In addition to the commonly dysregulated genes in HCM, such as markers of hypertrophy or fibrosis and calcium/potassium handling proteins, the expression of several genes regulating autophagy was also altered in HCM, some being upregulated (BCL2, BECN1, CHMP2B, EPG5, FYCO1, HDAC6, LAMP1, MTOR, NBR1, SQSTM1, and TFEB), others downregulated (BAG3, MAP1LC3B) when compared with nonfailing ( Figure 1F ; Table II in the Data  Supplement) . We then evaluated autophagic markers in 10-weekold and 60-week-old mice to explore changes during disease progression. We confirmed previously described higher p62 (nonsignificant) and LC3-II protein levels in 60-week-old, 23 but not in 10-week-old knockin mice ( Figure 2A through 2C) , suggesting that accumulation of p62 and LC3-II protein occurs late in the disease progression. Of note, however, LC3-I level was already higher in 10-week-old knockin than in WT mice (Figure 2A and 2C) . We then quantified the expression of a customized panel of mouse genes associated with heart failure, arrhythmias, and autophagy in ventricular RNA pools from 60-week-old knockin and WT mice. Knockin exhibited dysregulated expression of proteins regulating hypertrophy, fibrosis, calcium handling, cardiac action potential, and autophagy (Bag3, Bcl2, Becn1, Epg5, Erbb2, Fyco1, Hdac6, Nrg1, Rab7, and Sqstm1; Figure 2D ; Table III in the Data Supplement) .
Both human and mouse data suggest that autophagy is altered in HCM caused by MYBPC3 mutations.
Autophagic Flux Is Impaired in Knockin Mice
Measurement of basal levels of autophagic markers is not sufficient to conclude whether autophagy is activated or impaired. 29 Therefore, we next determined autophagic flux (macroautophagic activity) by evaluating LC3 turnover after injecting intraperitoneally 40 mg/kg of the lysosomal protease inhibitor leupeptin in mice for 1 hour. In hearts of 10-week-old mice, leupeptin treatment did not have any effect on the LC3-II level ( Figure 3A and 3B), whereas the treatment worked in liver in both knockin and WT mice ( Figure I in the Data Supplement). However, the LC3-II/LC3-I ratio was higher in WT than in knockin mice ( Figure 3B ). In hearts of 60-week-old mice, both LC3-II levels and the LC3-II/ LC3-I ratio were markedly higher in leupeptin-treated than in nontreated WT, whereas they did not differ between leupeptin-treated and nontreated knockin mice ( Figure 3A and 3B). This finding suggests an increased demand in autophagic activity in WT mice with aging, whereas the LC3 turnover was blunted in knockin mice.
To examine whether the impaired autophagic flux in knockin mice was because of the presence of mutant cMyBP-C or low level of cMyBP-C, we measured autophagic flux in 60-week-old Mybpc3-targeted knockout mice that do not express any cMyBP-C but develop a similar cardiac disease phenotype as knockin mice. 30 LC3 turnover was blunted in knockout mice to the same extent as in knockin mice ( Figure 3C and 3D). Although we cannot provide direct causality, these data suggest that low level of cMyBP-C rather than mutant cMyBP-C, in combination with pathological remodeling, induce impairment of autophagic flux.
Residual Bodies and Glycogen Accumulate in Knockin Mice
To assess autophagy-related ultrastructural differences between knockin and WT mice, we analyzed osmiumstained cryosections from 60-week-old knockin and WT mice using electron microscopy ( Figure 4 ). Terminal autolysosomes (residual bodies) containing cellular waste that was not broken down completely, probably resulting in lipofuscin or similar, markedly accumulated in knockin compared with WT mice ( Figure 4A Furthermore, we observed an accumulation of glycogen granula in knockin mice ( Figure 4B ; Figure III in the Data Supplement). Glycogen is degraded by the autophagic pathway, and an accumulation of glycogen granula is thought to be associated with impaired autophagy.
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Lysosomes Are Functional in Knockin Mice
To test whether the autophagy impairment is induced by a decrease in number or compromised function of lysosomes, we assessed protein levels and activity of the lysosomal protease cathepsin D and protein levels of the LAMP-2 (lysosome-associated membrane protein 2). No differences in the levels of the different cathepsin D forms were detected between 60-week-old knockin and WT mice ( Figure IVA and IVB in the Data Supplement). Consistent with these data, the cathepsin D activity did also not differ between knockin and WT ( Figure IVC in the Data Supplement). Protein levels of LAMP-2 were unaltered in the knockin mice as well ( Figure IVD and IVE in the Data Supplement). These findings suggest that lysosomal degradation is not affected in knockin mice.
Akt-Mammalian Target of Rapamycin Complex 1 Signaling Is Increased in Knockin Mice
mTORC1 (mammalian target of rapamycin complex 1) is a key negative regulator of autophagy and a recognized positive regulator of hypertrophy. 33 Hence, we evaluated mTORC1 signaling in 60-week-old knockin and WT mice ( Figure 5 ). Levels of phosphorylated proteins (activation) of mTOR and eukaryotic translation initiation factor p-4E-BP1 (phosphorylated 4E-binding protein 1), but not of ribosomal protein S6, were higher in knockin than in WT ( Figure 5A through 5D) . Levels of total mTOR and S6, but not of total 4E-BP1 were higher in knockin than in WT. Despite no difference in the ratio of phosphorylated:total proteins between the groups, increased phosphorylated mTOR and p-4E-BP1 levels suggest, at least in part, an increased mTORC1 signaling in knockin mice. This increase in mTORC1 We then evaluated which upstream pathways increased mTORC1 activity in knockin mice ( Figure 5E ; Figure VII in the Data Supplement). Dual phosphorylation (activation) of serine threonine kinase Akt/protein kinase B, evaluated by Akt Thr308 /Akt and Akt Ser473 /Akt ratios, was higher in knockin than in WT mice (Figure 5E ), whereas p-AMPK/AMPK (phosphorylated:total AMP-activated protein kinase), p-GSK3β (phosphorylated glycogen synthase kinase 3 beta), p-Erk1/2/Erk1/2 (phosphorylated:total extracellular signal-regulated kinase 1/2), and p-p38/p38 ratios did not differ between knockin and WT mice ( Figure VII in the Data Supplement). These data suggest that activated mTORC1 results from activation of Akt signaling.
Rapamycin Treatment or CR Partially Rescues Cardiomyopathy in Knockin Mice
To activate autophagy in knockin mice, we used rapamycin, an inhibitor of mTORC1, and CR, which also decreases mTORC1 activity. 34, 35 We evaluated whether these treatments could ameliorate cardiomyopathy in knockin mice. Eleven-week-old knockin and WT mice were subjected to a 9-week treatment with either 2.24 mg/kg·d rapamycin or 40% CR. At the beginning of the experiment, fractional area shortening was lower and left ventricular mass:body weight ratio was higher in knockin than WT mice, whereas body weight did not differ between knockin and WT, indicating systolic dysfunction and left ventricular hypertrophy (Figure 6A and 6B; Figure VIII in the Data Supplement). At the end of the treatment, fractional area shortening did not significantly differ between rapamycin-treated and untreated WT and knockin mice, whereas it was higher in CR-treated than in untreated knockin and WT mice ( Figure 6A ; Tables IV and V in the Data Supplement). The fractional area shortening difference of 10% between CR-treated and untreated knockin mice was significant, suggesting partial amelioration of cardiac function in knockin mice. As expected, body weight was markedly lower in CRtreated than in untreated knockin and WT mice, but was not affected by rapamycin treatment ( Figure 6B ). Heart weight:tibia length ratio was ≈30% higher in untreated knockin than in untreated WT mice and ≈24% lower in CR-treated knockin than in untreated knockin mice ( Figure 6C ), whereas tibia length did not differ between groups ( Figure 6E ). Lung weight:tibia length ratio was higher in untreated knockin than in untreated WT, indicating pulmonary edema induced by heart failure (Figure 6D) . Both rapamycin and CR treatments lowered lung weight:body weight in knockin, which did not differ from WT in these conditions (Figure 6D ), suggesting regression of heart failure in knockin mice.
Both treatments normalized the higher Bcl2 mRNA levels and lower Kcnj2 mRNA levels in knockin mice toward WT levels ( Figure 7A ; Table VI in the Data Supplement). In addition, rapamycin partially normalized the levels of markers of hypertrophy/heart failure (Atp2b4, Myh7, and Nppa), whereas CR reversed the altered gene expression of hypertrophy and fibrosis markers (Meox1, Col1a1, and Postn), the calcium-handling protein Cacna1g and autophagy regulating genes (Map1lc3b, Nrg1, and Rab7; Figure 7A ; Table VI in the Data Supplement). Furthermore, both treatments increased the LC3-II levels in both knockin and WT mice, indicating activation of autophagy ( Figure 7B and 7C) . Finally, LC3-II levels increased after leupeptin in untreated WT, but not in knockin mice, suggesting blunted LC3 turnover in knockin mice ( Figure 7B and 7C). The autophagic flux was restored in rapamycin-and CR-treated knockin mice.
DISCUSSION
In this study, we investigated autophagy in cardiomyopathy associated with MYBPC3 mutations in human HCM septal myectomies and in a Mybpc3-targeted knockin mouse model. Our major findings were (1) autophagy is altered in MYBPC3 mutation-carrying patients with HCM, (2) autophagy is impaired in knockin mice, and (3) activation of autophagy by rapamycin or CR ameliorates cardiomyopathy and autophagic flux in knockin mice.
LC3-II protein levels were higher in septal myectomies from patients with HCM carrying MYBPC3 mutations, indicating an alteration of autophagy. Although we cannot conclude whether there is activation or inhibition of autophagy in patients, data obtained in knockin mice argue for autophagy impairment. This was associated with dysregulated gene expression of several proteins regulating autophagy in both patients with HCM and knockin mice. LC3-II accumulation in the knockin mouse hearts was progressive and accompanied by autophagic flux impairment with age. Furthermore, residual bodies and glycogen, which are both degraded by autophagy, 31 ,32 accumulated in knockin mice. Glycogen accumulation was associated with left ventricular hypertrophy and was found in several diseases involving defective autophagy, for example, Pompe, Danon, and Fabry disease. 36 In contrast to the ubiquitin-proteasome system impairment, which was found only in aged knockin mice with markedly low amounts of mutant cMyBP-C, 23 autophagy impairment was common in both knockin and knockout mice, suggesting that cMyBP-C haploinsufficiency alone or in combination with cardiomyopathy is a trigger.
The involvement of autophagy in patients with HCM and animal models with mutations in sarcomeric proteins has not been studied in depth. Only a few inher- ited cardiomyopathies are known to be associated with a defect in autophagy. Deficiency of the principal lysosomal membrane protein LAMP-2 causes Danon disease involving severe HCM. 4 ,5 LEOPARD syndrome, caused by mutations in PTPN11 (protein tyrosine phosphatase, nonreceptor type 11), leads to increased phosphatidylinositol 3-kinase signaling associated with reduced autophagy and HCM.
6 Lamp2-deficient mice (Danon disease) showed accumulation of autophagic vesicles, 37 whereas PTPN11-targeted knockin mice (LEOPARD syndrome) 6 and phosphatase and tensin homolog (PTEN)-targeted knockout 38 showed increased mTORC1 signaling and decreased autophagic flux, all suggesting autophagy impairment. Vici syndrome, a rare autosomal-recessive inherited multisystem disorder involving cardiomyopathy, 7 is caused by mutations in EPG5, which encodes the ectopic P-granules autophagy protein 5, an essential protein for autophagic degradation. 39 Defective autophagy has been also reported in desmin-related cardiomyopathy caused by αB-crystallin or desmin mutations and associated with the accumulation of cytotoxic misfolded proteins, 9 in dilated cardiomyopathy caused by LMNA mutations 13, 14 or mutations in BAG3, 40, 41 encoding human BCL2 (B-cell chronic lymphocytic leukemia/ lymphoma 2)-associated athanogene 3 gene involved in selective macroautophagy. 42 Left ventricular noncompaction caused by a PLEKHM2 mutation was associated with a defective autophagy-lysosomal pathway and impairment of autophagic flux in patients' fibroblasts. 15 In the present study, mTORC1 signaling was elevated in knockin and knockout mice. mTORC1 negatively regulates autophagy initiation, but can also inhibit autophagosome-lysosome fusion. [43] [44] [45] In addition, mTORC1 negatively regulates transcription factor EB and thus inhibits transcription of autophagy and lysosomal genes. 46 Out of the several signaling pathways that are known to activate mTOR, we found that Akt/ PKB (protein kinase B) signaling was increased and likely contributed to mTORC1 activation in knockin mice. This was associated with the upregulation of Ctgf, encoding the connective tissue growth factor, which induced cardiomyocyte hypertrophy via Akt signaling, 47 and Bcl2, encoding BCL2, which can be upregulated via Akt signaling ( Figure 2D ). 48 Accumulation of BCL2 can sequester Beclin-1 or inhibit Bax/Bak-mediated apoptosis and thus inhibits autophagy. 49, 50 Similarly, BCL2, CTGF, and MTOR genes were upregulated in HCM ( Figure 1F ), suggesting activated mTORC1 in HCM.
Treatment with rapamycin or CR to inhibit mTORC1 activity and thereby activate autophagy partially rescued the cardiomyopathy phenotype or heart failure and restored the autophagic flux in knockin mice. The mechanism of action is not fully certain and rapamycin and CR may affect other cellular functions besides autophagy. However, our customized transcriptome analysis indicates normalization of expression of markers of hypertrophy, fibrosis, and also autophagy regulating genes. Specifically, the expression levels of both Bcl2 and Kcnj2, encoding the potassium inwardly rectifying channel, subfamily J, member 2 (Kir2.1), were both markedly dysregulated in knockin mice and were partially normalized toward levels found in WT mice with either treatment. Our data are in agreement with previous findings showing that rapamycin administration to mice with PTPN11 mutation, which resulted in activation of phosphatidylinositol 3-kinase pathway and increased mTORC1 activity, ameliorated cardiomyopathy. 6 Similarly, rapamycin treatment reversed hypertrophy in a PTEN-deficient mouse model with increased mTORC1 activity. 38 Moreover, rapamycin treatment or CR has been shown to have positive effects in different models of pressure overload-induced hypertrophy and age-related hypertrophy. 6, 38 Up to now, there are only general treatments like calcium channel blocker and β-blocker, septal myectomy, ethanol ablation, and heart transplantation available for human HCM. Here, we provide evidence that autophagy is defective in patients and mice with HCM carrying MYBPC3 mutations and that activation of autophagy ameliorates cardiomyopathy in mice. We therefore propose that activation of autophagy might be an attractive option alone or in combination with another approach to rescue HCM induced by MYBPC3 mutations. 
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